What Does a High or Low Lyme Disease Result Mean?

Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.

If you searched for “high low Lyme disease blood test”, you are probably looking at a lab report with terms like positive, negative, reactive, nonreactive, equivocal, IgM, IgG, ELISA, EIA, or Western blot bands. The most important starting point is this: a Lyme disease blood test is usually not interpreted like cholesterol, glucose, or a hormone level. A “high” Lyme result generally means antibodies were detected above the lab’s cutoff. A “low” result usually means antibodies were not detected at a level that meets the cutoff. Those numbers do not tell you how severe Lyme disease is, how long you have had it, or whether treatment has cured it.

How Lyme disease blood testing works

Lyme disease testing is different from many routine blood tests because it usually detects the immune response to infection rather than the organism itself. According to the CDC’s clinical testing guidance for Lyme disease, most Lyme disease tests are serologic antibody tests, and antibodies may take several weeks to develop after infection. That timing is why a person with very early infection can have a negative blood test, especially if testing occurs soon after a tick bite or soon after symptoms begin.

In the United States, recommended Lyme disease laboratory diagnosis generally uses a two-tier testing process. In standard two-tier testing, the first step is usually an enzyme immunoassay, often called an EIA or ELISA, or an immunofluorescence assay. If that first step is negative, no second step is recommended. If the first step is positive or equivocal, the lab performs a second test, historically an immunoblot or Western blot. Increasingly, laboratories also use modified two-tier testing, where two different EIAs are used instead of a Western blot. The CDC notes that both steps are required and that the overall result is positive only when the required first and second steps support a positive interpretation.

The 2020 IDSA/AAN/ACR Lyme disease guideline similarly recommends clinically validated tests used in conventional or modified two-tier protocols. The guideline also cautions against nonstandard tests such as urine antigen testing, nonvalidated DNA testing, lymphocyte transformation tests, and CD57 lymphocyte assays for routine clinical diagnosis because they lack adequate independent validation for that purpose.

What a high or positive Lyme disease result can mean

A “high,” “positive,” or “reactive” Lyme disease result usually means the test detected antibodies to the bacteria that cause Lyme disease. On a consumer lab report, you may see a numeric index value that is above the lab’s cutoff, or you may see words such as positive, reactive, or detected. The exact wording depends on the laboratory and the testing method.

However, a positive Lyme antibody result does not automatically mean you currently have an active infection requiring treatment. Antibodies can persist long after the initial infection. The CDC states that once antibody titers are elevated, they can remain elevated for months to years and cannot be used to determine cure. The Association of Public Health Laboratories’ reporting guidance also explains that IgG antibodies may remain detectable for months to years after infection has resolved and that response to therapy is assessed clinically, not by repeat antibody testing.

Report wording	Plain-language meaning	Important caution
Positive / reactive / detected	Antibodies were found at or above the lab’s cutoff.	Does not prove the infection is active or severe.
High index value	The antibody signal was above the reference cutoff for that assay.	Higher is not the same as “worse Lyme disease.”
IgM positive	May fit acute or recent infection if symptoms started within 30 days.	IgM-only positivity after 30 days can be misleading.
IgG positive	Can fit recent or past infection, depending on symptoms and exposure.	IgG may stay positive after successful treatment.
Equivocal / indeterminate	The result is near the cutoff or not clearly negative or positive.	Usually requires reflex testing or clinical follow-up.

A positive result is most useful when there is a compatible clinical story: recent or possible exposure to blacklegged ticks, time spent in a Lyme-endemic area, an expanding erythema migrans rash, facial palsy, meningitis-like symptoms, certain heart rhythm problems, or swelling of a large joint such as the knee. A positive result is less useful when the chance of Lyme disease is low before testing—for example, nonspecific long-term fatigue with no exposure risk and no objective signs—because false positives become more likely when testing people with low pretest probability.

What a low or negative Lyme disease result can mean

A “low,” “negative,” “nonreactive,” or “not detected” Lyme disease result means the test did not find enough antibodies to meet the laboratory’s threshold. If your first-tier screening test is negative, the CDC says no further testing is recommended in the usual two-step algorithm. In the right clinical context, a negative result can make Lyme disease less likely.

The main exception is early infection. If symptoms began very recently, your immune system may not yet have produced enough antibodies for detection. APHL guidance notes that negative results can occur in patients recently infected, particularly within 14 days, and if recent infection is suspected, repeat testing on a new sample collected in 7 to 14 days may be recommended. The CDC’s public testing page also explains that antibody tests may appear falsely negative during the first few weeks of infection and generally have better sensitivity after 4 to 6 weeks have passed.

A classic expanding erythema migrans rash is another important exception. In a person who lives in or has traveled to an area where Lyme disease is common, that rash can be enough for a clinical diagnosis and treatment may begin without waiting for blood test confirmation. The Mayo Clinic’s diagnosis overview makes the same practical point: in areas where Lyme is common, the rash may be sufficient for diagnosis.

IgM vs. IgG: why timing changes the meaning

Many Lyme disease reports separate antibodies into IgM and IgG. IgM is often described as an early antibody response, while IgG tends to become more prominent later and can persist. This simplified explanation is helpful, but it is easy to overinterpret. Lyme serology does not function as a perfect infection clock.

Pattern	Possible meaning	What to ask your clinician
IgM negative, IgG negative	No laboratory evidence of Lyme antibodies; can occur if no infection or if testing is very early.	Were symptoms early enough that repeat testing is reasonable?
IgM positive, IgG negative	Can fit acute or recent infection when symptoms are within 30 days.	When exactly did symptoms start? Is IgG seroconversion follow-up needed?
IgM negative, IgG positive	Can indicate infection in the recent or remote past.	Do current symptoms match active Lyme disease, past exposure, or another condition?
IgM positive, IgG positive	Can indicate recent or past infection; interpretation depends on clinical context.	Does the result match exposure history and objective signs?

The most common pitfall is treating an isolated IgM positive result as proof of Lyme disease long after symptoms began. The CDC specifically states that positive IgM results should be disregarded if the patient has been ill for more than 30 days. APHL guidance is similar: IgM immunoblot results should be considered evidence of recent infection only in patients presenting within 30 days of symptom onset, and considering IgM after more than 30 days is discouraged because of false-positive IgM results or prolonged IgM seropositivity.

What Western blot bands do—and do not—mean

Some Lyme disease reports list individual Western blot bands such as 23 kDa, 39 kDa, 41 kDa, or 93 kDa. These bands represent antibody reactivity to particular bacterial proteins. It is tempting to read each band as a separate diagnosis clue, but consumers should be cautious: individual bands are not meant to be interpreted in isolation.

Under standard two-tier testing, the first-tier EIA or ELISA determines whether immunoblot testing should be performed. Then the laboratory applies defined criteria to determine whether the IgM or IgG immunoblot is positive. A CDC review in Emerging Infectious Diseases describes conventional criteria: an IgM immunoblot is considered positive when at least 2 of 3 specified bands are present, while an IgG immunoblot requires at least 5 of 10 specified bands. Your report’s final interpretation is more important than one isolated band.

A single reactive band—especially a nonspecific band—does not equal confirmed Lyme disease. Conversely, if testing is performed too early, a person with true early infection may not yet have developed enough antibodies to meet criteria. This is why symptom timing, exposure history, and the full two-tier algorithm matter more than trying to self-diagnose from band patterns.

False positives, false negatives, and other limitations

No Lyme disease blood test is perfect. A false negative can occur if testing is done too soon after infection, before antibodies are detectable. Early antibiotic treatment can also reduce the chance of seroconversion, meaning some treated patients may not develop a strongly positive antibody response. A false positive can occur because antibodies cross-react with other infections or immune conditions. The CDC lists relapsing fever, syphilis, rheumatoid arthritis, and Epstein-Barr virus infection as examples of conditions that can cause false-positive cross-reactions.

Another limitation is that a positive antibody test cannot distinguish active infection from past infection. This matters for people who live in areas where Lyme disease is common, have had Lyme disease before, or were treated in the past. A new positive test may reflect old antibodies rather than a new illness. Diagnosis of reinfection depends on new exposure, new compatible symptoms, and clinical evaluation—not simply whether antibodies are still present.

Testing is also less useful when symptoms are vague and exposure risk is low. Fatigue, muscle aches, brain fog, headaches, and joint pain can occur with Lyme disease, but they can also occur with viral infections, autoimmune disease, thyroid disease, anemia, medication effects, sleep disorders, depression, long COVID, and many other conditions. The CDC emphasizes that clinicians should consider exposure likelihood, whether symptoms are clinically consistent with Lyme disease, other possible illnesses, and lab results when indicated.

How to prepare for a Lyme disease blood test

Lyme antibody testing usually requires a standard blood draw. Fasting is generally not required unless other tests are being collected at the same time. The most useful preparation is informational: write down the date of any tick bite, when symptoms began, whether you noticed a rash, where you may have been exposed, and whether you have taken antibiotics. If you have photos of an expanding rash, bring them to the appointment because the rash may fade before you are evaluated.

Also ask which testing algorithm the laboratory uses. You do not need to choose the assay yourself, but it is reasonable to ask whether the result reflects CDC-recommended standard two-tier testing or modified two-tier testing. If a report contains only a screening result without the appropriate follow-up step, interpretation may be incomplete.

Cost and ordering considerations

The cost of Lyme disease blood testing depends on how it is ordered, whether reflex testing is triggered, whether insurance is used, and whether a clinician visit, specimen collection fee, draw fee, or telehealth review fee is required. A first-tier antibody screen may cost less than a full reflexed two-tier workup, but the final cost to the patient can rise when confirmatory testing is performed or when separate visit and collection fees apply.

If you are paying out of pocket, compare the total effective cost, not only the advertised lab price. Ask whether the quoted price includes the blood draw, required clinician authorization, reflex confirmatory testing, taxes, processing fees, and result review. Also confirm whether the test is available in your state, where the specimen is collected, and whether positive or equivocal screens automatically reflex to the required second step. If you use insurance, ask your plan whether the ordering clinician, laboratory, and diagnosis code are covered and whether prior authorization is needed.

For most people, Lyme testing is most appropriate when ordered or reviewed by a clinician who can match the result to symptoms and exposure risk. Direct-to-consumer testing can be convenient, but a positive or confusing result still needs clinical interpretation, and a negative result should not be used to ignore a classic Lyme rash or concerning neurologic, cardiac, or joint symptoms.

Practical next steps after a high, low, or confusing result

• Check the full algorithm. Look for the first-tier result and the second-tier result. A screening positive alone is not the same as an overall positive two-tier test.
• Anchor the result to symptom timing. If symptoms started less than 2 weeks ago, a negative test may be too early. If symptoms have lasted more than 30 days, IgG usually matters more than IgM.
• Document exposure risk. Note outdoor activities, travel, tick attachment, rash, and whether you live in or visited an area where Lyme disease is common.
• Do not use antibodies as a cure marker. Repeat testing after treatment is usually not helpful because antibodies can remain detectable for months or years.
• Ask about alternative diagnoses. If symptoms are ongoing and Lyme testing is negative or does not fit the clinical picture, a broader evaluation may be more useful than repeated Lyme panels.
• Seek prompt care for red flags. Facial droop, severe headache with neck stiffness, fainting, chest pain, palpitations, shortness of breath, or a swollen painful joint should be evaluated urgently.

Some people continue to have fatigue, body aches, or thinking difficulties after treatment. The CDC describes this as post-treatment Lyme disease syndrome when symptoms persist after Lyme disease, and notes that the cause is not yet known. The CDC also discourages the term “chronic Lyme disease” because it implies ongoing infection when the cause of prolonged symptoms is uncertain. If symptoms persist, the most productive next step is usually a careful evaluation for lingering effects, complications, reinfection, coinfections when appropriate, and non-Lyme causes.

 

FAQs

Does a high Lyme antibody number mean a worse infection?

No. A higher antibody index or stronger reactive result does not reliably measure disease severity, bacterial load, or how long you have been infected. Lyme antibody tests are mainly used to support or argue against exposure to Lyme-causing bacteria in the right clinical setting.

Can I have Lyme disease with a negative blood test?

Yes, especially very early after infection. Antibodies may not be detectable during the first days or weeks. If symptoms are early and suspicion remains, a clinician may recommend repeat testing. A classic erythema migrans rash in a person with exposure risk can be diagnosed clinically without waiting for a positive test.

Can I have a positive test but not need treatment?

Yes. A positive IgG can reflect past infection or treated infection. Whether treatment is appropriate depends on current symptoms, physical findings, exposure history, and whether the result fits a recommended testing algorithm.

Why did my screening test say positive but the final result says negative?

In two-tier testing, a first-tier screen is designed to be sensitive. If it is positive or equivocal, the second-tier test checks whether the antibody pattern is specific enough to confirm Lyme disease. If the second step is negative, the overall interpretation may be “not confirmed” or negative.

Should I repeat a Lyme test after antibiotics?

Usually no. Antibodies can remain positive long after treatment, so repeat antibody testing is not a reliable way to prove cure. Follow-up is based on symptoms, exam findings, and whether new objective signs appear.

Are home or direct-to-consumer Lyme tests reliable?

Quality depends on the test method, specimen collection, laboratory, and whether the result follows a validated two-tier algorithm. Convenience does not replace interpretation. If you use an at-home or direct-order option, confirm the lab method, reflex testing process, collection requirements, total cost, and how abnormal results are reviewed.

What if my report shows only one positive Western blot band?

One band by itself is not the same as a confirmed positive Lyme disease result. The laboratory’s final interpretation and the full two-tier sequence are what matter clinically.

Can Lyme testing detect other tick-borne infections?

No. A Lyme antibody test is aimed at Lyme-causing Borrelia species. It does not rule out other tick-borne illnesses such as anaplasmosis, babesiosis, ehrlichiosis, Rocky Mountain spotted fever, or other regional infections. Symptoms, geography, blood counts, liver enzymes, smear, PCR, or other targeted tests may be needed depending on the situation.

Sources

• CDC: Clinical Testing and Diagnosis for Lyme Disease
• CDC: Testing and Diagnosis for Lyme Disease
• Association of Public Health Laboratories: Suggested Reporting Language, Interpretation and Guidance for Lyme Disease Serologic Testing Results
• IDSA/AAN/ACR: 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
• CDC Emerging Infectious Diseases: Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease
• CDC: Chronic Symptoms and Lyme Disease
• Mayo Clinic: Lyme Disease Diagnosis and Treatment